A Phase I/II Trial Of ZD1839 (Iressa) [gefitinib] And Radiation In Pediatric Patients Newly Diagnosed With Brain Stem Tumors Or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited To Brain Stem Tumors

Trial Profile

A Phase I/II Trial Of ZD1839 (Iressa) [gefitinib] And Radiation In Pediatric Patients Newly Diagnosed With Brain Stem Tumors Or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited To Brain Stem Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2011

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Sep 2010 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 07 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top